Inactive Instrument

BLIRT S.A.

BLR

PLBLIRT00018

BLIRT S.A. announced that it has received PLN 0.84 million in funding from N50 Cyprus Limited

March 08, 2018

On March 9, 2018, BLIRT S.A. (WSE:BLR) closed the transaction.

Latest news about BLIRT S.A.

BLIRT S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Qiagen N.V. completed the acquisition of 96.3% stake in BLIRT S.A. from N50 Cyprus Limited, Marian Popinigis and others for $64 million.	22-06-29	CI
Sector Update: Health Care Stocks Edging Lower Ahead of Wednesday Close	22-05-11	MT
Sector Update: Health Care Stocks Still Hanging on for Small Advance	22-05-11	MT
Qiagen to Acquire 96% Stake In BLIRT for Undisclosed Sum	22-05-11	MT
Qiagen N.V. agreed to acquire 96.3% stake in BLIRT S.A. from N50 Cyprus Limited, Marian Popinigis and others.	22-05-10	CI
BLIRT S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-14	CI
BLIRT S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-14	CI
BLIRT S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
BLIRT S.A. Announces Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Blirt S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
BLIRT S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-15	CI
Agencja Rozwoju Pomorza S.A. cancelled the acquisition of the remaining 76.91% stake in Transmedium Tadeusz Macha from BLIRT S.A..	19-07-02	CI
Agencja Rozwoju Pomorza S.A. signed a share purchase agreement to acquire the remaining 76.91% stake in Transmedium Tadeusz Macha from BLIRT S.A. for approximately PLN 160 million.	18-07-02	CI
BLIRT S.A. announced that it has received PLN 0.84 million in funding from N50 Cyprus Limited	18-03-08	CI
BLIRT S.A. announced that it expects to receive PLN 0.84 million in funding from N50 Cyprus Limited	18-02-21	CI

Blirt SA is a Poland-based company, which is involved in the production of specialized enzymes and reagents dedicated to use in Life Science. The Company develops protein production methods (upstream and downstream) and conducting production on an industrial scale. Other product groups in which entity is specializing are kits for nucleic acid isolation, reverse transcription reagents and Real-Time PCR.

Sector

More about the company

BLIRT S.A.

Equities

BLR

PLBLIRT00018

BLIRT S.A. announced that it has received PLN 0.84 million in funding from N50 Cyprus Limited

Latest news about BLIRT S.A.

Chart BLIRT S.A.

Company Profile